COPD clinical trials in Tennessee
16 studies for COPD are looking for participants at sites in Tennessee.
Cities in Tennessee
Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3)
- M3 Wake Research, Inc. ( Site 4440), Chattanooga
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Nov 6, 2026 · NCT07874815A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- Research Site, Chattanooga
- Research Site, Franklin
RecruitingPhase 2
Ages 40 and older · All sexes · Updated Oct 23, 2026 · NCT07082738Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- Chattanooga Research and Medicine- Site Number : 8400026, Chattanooga
- Premier Research Center, Llc- Site Number : 8400146, Hendersonville
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Oct 23, 2026 · NCT07190222A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Clinical Trials Center of Middle Tennessee, LLC, Franklin
- Premier Research Center, LLC, Hendersonville
RecruitingPhase 2/3
Ages 35 to 80 · All sexes · Updated Oct 22, 2026 · NCT07363694Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators
- The University of Tennessee Graduate School of Medicine, Knoxville
RecruitingPhase 4
Ages 40 and older · All sexes · Updated Oct 19, 2026 · NCT07133880Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- Meharry Medical College- Site Number : 8400133, Nashville
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Oct 19, 2026 · NCT07190209A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
- Research Site, Hendersonville
- Research Site, Knoxville
- Research Site, Lebanon
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Oct 9, 2026 · NCT06878261Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
- GSK Investigational Site, Knoxville
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Oct 5, 2026 · NCT06961214Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
- GSK Investigational Site, Franklin
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Oct 5, 2026 · NCT06959095A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Chattanooga
- Research Site, Franklin
- Research Site, Tullahoma
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Oct 2, 2026 · NCT06283966An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema
- Fort Sanders Regional Medical Center (StatCare), Knoxville
Recruiting
Ages 40 to 80 · All sexes · Updated Sep 17, 2026 · NCT06035120Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
- Vanderbilt University Medical Center, Nashville
RecruitingPhase 2
Ages 40 and older · All sexes · Updated Sep 4, 2026 · NCT07059091A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
- Research Site, Franklin
- Research Site, Johnson City
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Sep 3, 2026 · NCT06883305eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- GSK Investigational Site, Knoxville
RecruitingPhase 3
Ages 40 to 75 · All sexes · Updated Jul 28, 2026 · NCT07177339Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
- Methodist LeBonheur Healthcare, Memphis
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jul 10, 2026 · NCT05181826Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
- The Jackson Clinic, PA, Jackson
RecruitingObservational study
Ages 50 and older · All sexes · Updated Aug 5, 2025 · NCT06122077From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.